By Dr Benjamin Daniels

Journal articles

Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA, 2019, 'Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients', Pharmacoepidemiology and Drug Safety, 28, pp. 812 - 820, http://dx.doi.org/10.1002/pds.4751

Lord SJ; Kiely BE; Pearson SA; Daniels B; O'Connell DL; Beith J; Bulsara MK; Houssami N, 2019, 'Metastatic breast cancer incidence, site and survival in Australia, 2001-2016: A population-based health record linkage study protocol', BMJ Open, 9, http://dx.doi.org/10.1136/bmjopen-2018-026414

Brett J; Zoega H; Buckley NA; Daniels BJ; Elshaug AG; Pearson SA, 2018, 'Choosing wisely? Quantifying the extent of three low value psychotropic prescribing practices in Australia', BMC Health Services Research, 18, pp. 1009, http://dx.doi.org/10.1186/s12913-018-3811-5

Tan SYS; O’Neill S; Goldstein D; Ward RL; Daniels B; Vajdic CM, 2018, 'Predictors of care for patients with cancer of unknown primary site in three Australian hospitals', Asia Pacific Journal of Clinical Oncology, 14, pp. e512 - e520, http://dx.doi.org/10.1111/ajco.12815

Lopez D; Daniels B; Sanfilippo F; Pearson S; Martini A; Preen DB, 2018, 'Needs and priority areas for building capacity for working with linked data in the Australian pharmacoepidemiology workforce', International Journal of Population Data Science, 3, http://dx.doi.org/10.23889/ijpds.v3i4.733

Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA, 2018, 'Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)', Breast Cancer Research and Treatment, 171, pp. 151 - 159, http://dx.doi.org/10.1007/s10549-018-4804-0

Daniels B; Girosi F; Tervonen H; Kiely BE; Lord SJ; Houssami N; Pearson SA, 2018, 'Adherence to prescribing restrictions for her2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)', Plos One, 13, http://dx.doi.org/10.1371/journal.pone.0198152

Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA, 2018, 'Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001–2016)', Breast, 38, pp. 7 - 13, http://dx.doi.org/10.1016/j.breast.2017.11.007

Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE, 2018, 'ROR1 and ROR2 play distinct and opposing roles in endometrial cancer', Gynecologic Oncology, 148, pp. 576 - 584, http://dx.doi.org/10.1016/j.ygyno.2018.01.025

Daniels B; Kiely BE; Houssami N; Lord SJ; Dobbins T; Lu CY; Ward RL; Pearson S-A, 2018, 'Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014)', BRITISH JOURNAL OF CANCER, 118, pp. 441 - 447, http://dx.doi.org/10.1038/bjc.2017.405

Harris CA; Daniels B; Ward RL; Pearson SA, 2017, 'Retrospective comparison of Australia's Pharmaceutical Benefits Scheme claims data with prescription data in HER2-positive early breast cancer patients, 2008-2012', Public Health Research and Practice, 27, http://dx.doi.org/10.17061/phrp2751744

Brett J; Daniels B; Karanges EA; Buckley NA; Schneider C; Nassir A; McLachlan AJ; Pearson SA, 2017, 'Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study', British Journal of Clinical Pharmacology, 83, pp. 2581 - 2588, http://dx.doi.org/10.1111/bcp.13369

Brett J; Karanges EA; Daniels B; Buckley NA; Schneider C; Nassir A; Zoega H; McLachlan AJ; Pearson SA, 2017, 'Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure', Australian and New Zealand Journal of Psychiatry, 51, pp. 990 - 999, http://dx.doi.org/10.1177/0004867417721018

Daniels B; Lord SJ; Kiely BE; Houssami N; Haywood P; Lu CY; Ward RL; Pearson SA, 2017, 'Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort', BMJ Open, 7, http://dx.doi.org/10.1136/bmjopen-2016-014439

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2017, 'Validation of specificity of antibodies for immunohistochemistry: the case of ROR2', Virchows Archiv an International Journal of Pathology, 470, pp. 99 - 108, http://dx.doi.org/10.1007/s00428-016-2019-5

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2016, 'Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2 (Virchows Archiv, (2016), 10.1007/s00428-016-2019-5)', Virchows Archiv, 469, pp. 717, http://dx.doi.org/10.1007/s00428-016-2036-4

Vajdic CM; Mayson E; Dodds AJ; O'Brien T; Wilcox L; Nivison-Smith I; Le Marsney R; Daniels B; Ashton LJ; Tan J; Bilmon I; Aarons D; Tran S; Gibson J; Johnston A; Greenwood M; Forbes M; Hertzberg M; Huang G; Spencer A; Muirhead J; Szer J; Mason K; Lewis I; To C; Durrant S; Western R; Cannell P; Buffery S; Oswald C; Nelson A; Shaw P; Pearson L; Tiedemann K; Scoyne M; Fraser C; Seljak J; Cole C; Rowland K; Gough H; Tapp H; Green N; Moa A; McRae J; Jenkins M; Hicks J; Chaplin K, 2016, 'Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study', Biology of Blood and Marrow Transplantation, 22, pp. 949 - 956, http://dx.doi.org/10.1016/j.bbmt.2016.01.027

Cairns R; Daniels B; Wood DA; Brett J, 2016, 'ADHD medication overdose and misuse: The NSW poisons information centre experience, 2004-2014', Medical Journal of Australia, 204, pp. 154 - 154.e7, http://dx.doi.org/10.5694/mja15.00791

Cairns R; Daniels B; Wood DA; Brett J, 2016, 'ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004-2014', The Medical journal of Australia, 204, pp. 154

Mellish L; Karanges EA; Litchfield MJ; Schaffer AL; Blanch B; Daniels BJ; Segrave A; Pearson SA, 2015, 'The Australian Pharmaceutical Benefits Scheme data collection: A practical guide for researchers', BMC Research Notes, 8, pp. 634, http://dx.doi.org/10.1186/s13104-015-1616-8

Blanch B; Daniels B; Litchfield M; Pearson SA, 2015, 'Looking forward and looking back: The balancing act in new drug user designs for pharmacoepidemiological research', Pharmacoepidemiology and Drug Safety, 24, pp. 1117 - 1119, http://dx.doi.org/10.1002/pds.3848

Ward RL; Laaksonen MA; van Gool K; Pearson SA; Daniels B; Bastick P; Norman R; Hou C; Haywood P; Haas M, 2015, 'Cost of cancer care for patients undergoing chemotherapy: The elements of cancer care study', Asia Pacific Journal of Clinical Oncology, 11, pp. 178 - 186, http://dx.doi.org/10.1111/ajco.12354

Nelson AS; Ashton LJ; Vajdic CM; Le Marsney RE; Daniels B; Nivison-Smith I; Wilcox L; Dodds AJ; O'Brien TA; Moa A, 2015, 'Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy', Leukemia, 29, pp. 441 - 447, http://dx.doi.org/10.1038/leu.2014.203

Henry C; Quadir A; Hawkins NJ; Jary E; Llamosas E; Kumar D; Daniels B; Ward RL; Ford CE, 2015, 'Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling', Journal of Cancer Research and Clinical Oncology, 141, pp. 243 - 254, http://dx.doi.org/10.1007/s00432-014-1824-y

Bilmon IA; Ashton LJ; Le Marsney RE; Dodds AJ; O'brien TA; Wilcox L; Nivison-Smith I; Daniels B; Vajdic CM; Dodds A; Tan J; Aarons D; Tran S; Gibson J; Johnston A; Greenwood M; Forbes M; Hertzberg M; Huang G; Spencer A; Muirhead J; Szer J; Mason K; Lewis I; To C; Durrant S; Western R; Cannell P; Buffery S; Oswald C; Nelson A; Shaw P; Pearson L; Tiedemann K; Scoyne M; Fraser C; Seljak J; Cole C; Rowland K; Gough H; Tapp H; Green N; Moa A; McRae J; Jenkins M; Hicks J; Chaplin K, 2014, 'Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: A population-based cohort study', Bone Marrow Transplantation, 49, pp. 691 - 698, http://dx.doi.org/10.1038/bmt.2014.13

Couttas TA; Kain N; Daniels B; Lim XY; Shepherd C; Kril J; Pickford R; Li H; Garner B; Don AS, 2014, 'Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis', Acta Neuropathologica Communications, 2, http://dx.doi.org/10.1186/2051-5960-2-9

Abuhusain HJ; Matin A; Qiao Q; Shen H; Kain N; Day BW; Stringer BW; Daniels B; Laaksonen MA; Teo C; McDonald KL; Don AS, 2013, 'A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis', Journal of Biological Chemistry, 288, pp. 37355 - 37364, http://dx.doi.org/10.1074/jbc.M113.494740

Conference Papers

Ho JN; Hillen J; Nassar N; Zoega H; Beukelman T; Pratt N; Daniels B, 2026, 'Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study', in Pharmacoepidemiology and Drug Safety, http://dx.doi.org/10.1002/pds.70412

Gisev N; Buizen L; Schaffer A; Daniels B; Pearson S-A; Dobbins T; Blyth F; Larney S; Currow DC; Wilson A; Degenhardt L, 2022, '| New South Wales, Long-term trajectories of prescription opioid use in New South Wales, Australia', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, pp. 371 - 372, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859084401349&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Koch FC; Olivier J; Pearson S-A; Daniels B, 2022, 'A multivariate interrupted time series analysis assessing the impacts of half-pack sizes and increased access restrictions on publicly subsidized opioids in Australia', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, pp. 541 - 542, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859084402279&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Franchini F; Trapani K; Gillett P; Degeling K; Daniels B; Pearson S; Yang O; Zhang Y; Gibbs P; Ben S; McArthur G; Desai J; Fox S; IJzerman M, 2022, 'The PRIMCAT cohort study: Analysis of treatment utilisation, costs, and outcomes in Victoria for patients with cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 180 - 181

Tang M; Daniels B; Aslam M; Schaffer AL; Pearson S-A, 2021, 'Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 69 - 70, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Havard A; Chidwick K; Daniels B; Thistlethwaite J; Myton R; Blogg S; Wall M; Quick L; Pollack A; Manski-Nankervis J-A, 2021, '763Validity of algorithms for identifying five chronic conditions in MedicineInsight, Australian national primary care data', in International Journal of Epidemiology, Oxford University Press (OUP), pp. dyab168.270, http://dx.doi.org/10.1093/ije/dyab168.270

Tang M; Schaffer A; Kiely B; Daniels B; Lee C; Simes J; Pearson S-A, 2021, 'Cardiac assessment in Australian patients receiving trastuzumab for HER2+early breast cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 30 - 30, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000050&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lord S; Daniels B; Kiely B; O'Connell D; Pearson S-A; Beith J; Bulsara M; Houssami N, 2021, 'Long-term risk of distant metastasis and post-metastasis survival for breast cancer: health record linkage study', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000695815900386&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Liu D; Enriquez L; Daniels B; O'Mara T; Tang K; Ford C, 2021, 'Abstract PO042: ROR2 is epigenetically regulated in endometrial cancer', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. po042 - po042, http://dx.doi.org/10.1158/1557-3265.endomet20-po042

Daniels B; Kiely BE; Lord SJ; Houssami N; Pearson S-A, 2018, 'Abstract P2-12-01: Real-world use and outcomes of trastuzumab for HER2+ metastatic breast cancer in Australia: Analysis of the herceptin program, 2001-2015', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs17-p2-12-01

Harris C; Daniels B; Ward R; Pearson S-A, 2014, 'Do Pharmaceutical Claims Accurately Reflect Oncology Prescribing Practice: Evidence from an Australian HER2+Early Breast Cancer Cohort (HER2EBC)', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY-BLACKWELL, pp. 465 - 466, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342763600858&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Pearson S-A; Daniels B; Ward R, 2014, 'HER2 Positive Early Breast Cancer (HER2EBC): An Australian Patterns of Care Study', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY-BLACKWELL, pp. 468 - 468, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342763600863&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris CA; Ward RL; Daniels B; Pearson S, 2013, 'Do pharmaceutical claims accurately reflect oncology prescribing practice? Evidence from an Australian HER2+early breast cancer cohort ( HER2EBC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Diego, presented at ASCO's Quality Care Symposium, CA, San Diego, 01 November 2013 - 02 November 2013, http://dx.doi.org/10.1200/jco.2013.31.31_suppl.100

Harris CA; Pearson S; Daniels B; Srasuebkul P; Ward RL, 2013, 'HER2-positive early breast cancer (HER2EBC): An Australian pattern of care study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Diego, presented at ASCO's Quality Care Symposium, CA, San Diego, 01 November 2013 - 02 November 2013, http://dx.doi.org/10.1200/jco.2013.31.31_suppl.101

Conference Presentations

Daniels B, 2019, 'Identifying incident cancer cases in medicine dispensing claims: A validation study using Australia’s Pharmaceutical Benefits Scheme (PBS) data', presented at Asian Conference on Pharmacoepidemiology & Therapeutic Risk Management, 11 October 2019 - 13 October 2019

Daniels B, 2019, 'Validating administrative health data in Australia', presented at Asian Conference on Pharmacoepidemiology, Kyoto, Japan, 11 October 2019 - 13 October 2019

Daniels B, 2019, 'A Day in the Life: Prescription Medicine Use in Australia', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA, USA, 26 August 2019 - 28 August 2019

Daniels B; Pearson S, 2019, 'Understanding Treatment Pathways for HER2-Positive Metastatic Breast Cancer (HER2+MBC) Patients: Analysis Using Group-Based Trajectory Models (GBTM)', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czechia, 24 August 2019 - 26 August 2019

Daniels B; Pearson S, 2017, 'Real-world use and outcomes of trastuzumab for HER2+ metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2015', presented at San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 06 December 2017 - 10 December 2017

Daniels B; Pearson S, 2017, 'Patterns of care and outcomes for long-term survivors with HER2-positive metastatic breast cancer (HER2+MBC) starting trastuzumab: An Australian whole-of-population cohort study', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, 13 November 2017 - 15 November 2017

Daniels B, 2017, 'Patterns of care for long-term surviving trastuzumab-treated patients with HER2-positive metastatic breast cancer (HER2+MBC): an Australian whole-of-population cohort study', presented at Asian Conference on Pharmacoepidemiology & Therapeutic Risk Management., 30 October 2017 - 01 November 2017

Daniels B; Pearson S, 2017, 'Did a policy to ease the prescribing restrictions for lapatinib as second-line HER2-positive metastatic breast cancer increase initiation rates?', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, QC, Canada, 26 August 2017 - 28 August 2018

Daniels B; Pearson S, 2016, 'Real-word use and outcomes of trastuzumab for metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2014', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Gold Coast, QLD, 15 November 2016 - 17 November 2016

Back to profile page